Kaçar CK, et al. - In this prospective observational study among patients with septic shock and acute kidney injury, researchers assessed the efficacy of HA330 hemoperfusion adsorbent application with renal replacement therapy. Participants included 23 patients who received a diagnosis of sepsis and received continuous venovenous hemodiafiltration and HA330 hemoperfusion for 2 h once daily for 3 days. Experts assessed the effectiveness of HA330 hemoperfusion by comparing certain parameters on days 0 and 1, 1 and 2, and 2 and 3. After the first application of HA330 hemoperfusion, a significant rise in pH was noted, a significant drop in C-reactive protein (CRP) and procalcitonin levels was evident following the second application, and the CRP level declined significantly after the third application. Overall, improved levels of CRP and heart rate were evident following the application of HA330 hemoperfusion 2 h daily for 3 consecutive days, however, no effect was evident on others or on the prognosis.